A large number of pharmaceutical companies are busy divesting assets!

In recent years, with the normalization of centralized drug procurement and the continuous advancement of medical insurance negotiations, pharmaceutical companies have been under obvious pressure on profits, and generally face challenges in many aspects such as cost control
.
In order to have a better development status, many pharmaceutical companies choose to actively focus on their main business and accelerate their "slimming"
.
In more than a month from the end of 2021 to the present, a large number of pharmaceutical companies, including Ruikang Pharmaceuticals, Yunnan Baiyao, and Xianju Pharmaceutical, have been busy divesting assets
.
For example, on January 19, Ruikang Pharmaceutical announced that the company planned to transfer 51% of the shares of Honglin Pharmaceutical, and Wang Hongliang took over
.
According to the announcement, the legal representative of Honglin Pharmaceutical is Wang Hongliang, and the company's business scope includes Chinese patent medicine, Chinese herbal decoction pieces, and chemical pharmaceutical preparations
.
The company was previously held 51% by Ruikang Pharmaceuticals and 49% by Wang Hongliang, and is currently wholly-owned by Wang Hongliang
.
On January 18, Xianju Pharmaceutical announced that it planned to transfer 61.
2% of the shares of its holding subsidiary, Haisheng Pharmaceutical, and would no longer hold the company's equity after the transfer was completed
.
It is reported that the main business of its subsidiary Haisheng Pharmaceutical is the manufacture of vitamin D3 APIs.
Due to the continuous investment in subsequent production transformation and new product expansion, it is uncertain.
Xianju Pharmaceutical will focus on steroid hormones according to its development plan.
Therefore, the company chose to list and transfer the equity
.
Prior to this, Xianju Pharmaceutical also transferred part of the waste machinery and equipment assets in the Chengnan plant at a transaction price of 20.
3316 million yuan
.
On January 12, Asia Pacific Pharmaceuticals announced that the shareholder Bank of Ningbo plans to transfer the 39 million shares it holds to Fubon Group through a transfer agreement, with a total transfer price of RMB 203.
19 million
.
After the completion of the share transfer, Fubon Group's shareholding ratio will increase to 14.
38%
.
It is worth mentioning that Asia Pacific Pharmaceuticals recently gained four consecutive boards due to the concept of "Helicobacter pylori".
Affected by this news, it hit the daily limit again on January 12.
As of the close of January 12, the stock price has increased by 71.
87% this year.

.
On January 7, Shuangcheng Pharmaceutical announced that it agreed that Ningbo Shuangcheng Pharmaceutical, a holding subsidiary of the company, plans to acquire specific intellectual property rights and production technologies related to memantine hydrochloride tablets (5mg, 10mg) for RMB 6 million.
Rights in China are granted to Baishan Pharmaceuticals
.
The announcement shows that in April 2020, Ningbo Shuangcheng's new drug application for memantine hydrochloride tablets was approved by the US FDA for marketing authorization
.
The US FDA reviewed the memantine hydrochloride tablet ANDA, recognized the comprehensiveness and scientificity of the application information, and believed that the company's product was consistent with the original drug company's reference drug Namenda in terms of bioequivalence and efficacy
.
At present, the US rights holder of Memantine Hydrochloride Tablets is still Ningbo Shuangcheng
.
Earlier, there was also a 100% stake in Shanghai Yunzhen Medical, a tertiary wholly-owned subsidiary held by a secondary wholly-owned subsidiary of Yunnan Baiyao, which was transferred to the group company; The assets of the vaccine plant are listed for transfer; Tai'antang Pharmaceutical plans to transfer 100% equity of Tai'an Investment Development Co.
, Ltd.
for 240 million yuan
.
Behind the accelerated divestment of assets by a large number of pharmaceutical companies, the industry reshuffle is accelerating
.
At present, the national procurement has entered the sixth round.
With the normalization of centralized procurement, the survival of traditional generic drug companies that cannot adapt to changes in the industry will be more difficult, and transformation and upgrading have become a major trend
.
In this context, pharmaceutical companies are either being acquired, or accelerating their transformation and upgrading by themselves
.
In the process of a series of mergers and acquisitions, business and product integration will be inevitable
.
The industry believes that spin-offs can reduce the internal friction of pharmaceutical companies to a certain extent, improve efficiency, and at the same time help to make the development path of the company clearer
.